• Product NameBDA-366
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivitySmall-molecule BDA-366 specifically targets the BH4 domain of Bcl2 BDA-366 suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change. Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγnull mice, without significant cytotoxic effects on normal hematopoietic cells or body weight. Thus, BDA-366 functions as a novel BH4-based BCL2 inhibitor and offers an entirely new tool for MM therapy.
• Target NameBcr-Abl inhibitor
• CAS No. 1821496-27-8
• Calculated MW 423.26
• Formulation C24H29N3O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CCN(CC)C[C@@H](O)CNC1=CC=C(NC[C@@H]2OC2)C3=C1C(C4=C(C3=O)C=CC=C4)=O
  Pathways:Angiogenesis; Cytoskeletal Signaling
  Receptor:Bcl-2-BH4
  Boling pt:
  Melting pt:
  Solubility:DMSO: 84 mg/mL (198.34 mM); Ethanol: 5 mg/mL (11.8 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Deng J, et al. Oncotarget. 2016, 7(19):27753-63.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting